8.3536
Zenas Biopharma Inc stock is traded at $8.3536, with a volume of 76,928.
It is up +2.44% in the last 24 hours and up +17.79% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$8.21
Open:
$8.09
24h Volume:
76,928
Relative Volume:
0.29
Market Cap:
$353.83M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+15.68%
1M Performance:
+17.79%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ZBIO
Zenas Biopharma Inc
|
8.375 | 353.83M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.32 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.58 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.34 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
240.03 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
253.00 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-04-25 | Initiated | Wolfe Research | Outperform |
Dec-16-24 | Initiated | H.C. Wainwright | Buy |
Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
Oct-08-24 | Initiated | Citigroup | Buy |
Oct-08-24 | Initiated | Guggenheim | Buy |
Oct-08-24 | Initiated | Jefferies | Buy |
Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth? - Yahoo Finance UK
Zenas BioPharma’s Obexelimab: A Promising Therapy with a Buy Rating and $30 Price Target - TipRanks
Certain Common Stock of Zenas BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2025. - Marketscreener.com
Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView
Zenas BioPharma Targets Key 2025 Milestones For Obexelimab In Autoimmune Diseases - BERNAMA
Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma! - TipRanks
Zenas BioPharma director Xiao Ting purchases $77,600 in common stock By Investing.com - Investing.com Australia
Zenas BioPharma director Xiao Ting purchases $77,600 in common stock - Investing.com
ZENAS BIOPHARMA TARGETS KEY 2025 MILESTONES FOR OBEXELIMAB IN AUTOIMMUNE DISEASES - BERNAMA
ZENAS BIOPHARMA ANNOUNCES KEY 2024 ACCOMPLISHMENTS AND 2025 BUSINESS OBJECTIVES TO SUPPORT THE GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF THERAPIES FOR AUTOIMMUNE DISEASES - BERNAMA
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives - Marketscreener.com
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases - Wahanariau
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 - GlobeNewswire
Biotech Powerhouse: Zenas BioPharma's $350M War Chest Fuels Triple Clinical Trial Assault on Autoimmune Diseases - StockTitan
Wolfe Research Initiates Coverage of Zenas BioPharma (ZBIO) with Outperform Recommendation - MSN
Zenas BioPharma initiated with an Outperform at Wolfe Research - MSN
Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target - Marketscreener.com
Zenas Biopharma To Present At Guggenheim SMID Cap Biotech Conference On Feb 5 - BERNAMA
ZENAS BIOPHARMA TO PRESENT AT THE GUGGENHEIM SMID CAP BIOTECH CONFERENCE - BERNAMA
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Zenas BioPharma Takes Center Stage: Key Revelations Expected at Major Biotech Summit - StockTitan
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
Zenas BioPharma initiated with a Buy at H.C. Wainwright - Yahoo Finance
HC Wainwright & Co. Initiates Coverage of Zenas BioPharma (ZBIO) with Buy Recommendation - MSN
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
H.C. Wainwright starts Zenas stock with Buy rating, eyes Obexelimab’s role in autoimmune treatment - Investing.com Australia
Guggenheim maintains buy on ZBIO shares, sees strong drug potential By Investing.com - Investing.com Canada
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley - Yahoo Finance
Zenas BioPharma CEO Leon O. Moulder Jr. purchases $718,100 in stock - Investing.com
Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 - Investing.com
Zenas BioPharma Inc. (ZBIO) Quarterly 10-Q Report - Quartz
FMR LLC Acquires New Stake in Zenas BioPharma Inc - GuruFocus.com
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Raises $259M in IPO, Advances Phase 3 Trial Amid Growing R&D Investment | ZBIO Stock News - StockTitan
Zenas BioPharma Completes Targeted Enrollment of the Phase - GlobeNewswire
Zenas BioPharma Hits Milestone: Completes Enrollment in Largest-Ever IgG4-RD Trial | ZBIO Stock News - StockTitan
Zenas BioPharma To Attend Upcoming Healthcare Investor Conferences - BERNAMA
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences - BERNAMA
TSX Global Base Metals EW Index (TXBE) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):